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Abstract
Initiation of warfarin therapy using trial-and-error dosing is problematic. our goal was to develop
and validate a pharmacogenetic algorithm. in the derivation cohort of 1,015 participants, the
independent predictors of therapeutic dose were: VKORC1 polymorphism −1639/3673 g>a (−28%
per allele), body surface area (Bsa) (+11% per 0.25 m2), CYP2C9*3 (−33% per allele), CYP2C9*2
(−19% per allele), age (−7% per decade), target international normalized ratio (inr) (+11% per 0.5
unit increase), amiodarone use (−22%), smoker status (+10%), race (−9%), and current thrombosis
(+7%). This pharmacogenetic equation explained 53−54% of the variability in the warfarin dose in
the derivation and validation (N = 292) cohorts. For comparison, a clinical equation explained only
17−22% of the dose variability (P < 0.001). in the validation cohort, we prospectively used the
pharmacogenetic-dosing algorithm in patients initiating warfarin therapy, two of whom had a major
hemorrhage. To facilitate use of these pharmacogenetic and clinical algorithms, we developed a
nonprofit website, http://www.WarfarinDosing.org.
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Initiation of therapy with the anticoagulant warfarin sodium (Coumadin and others) protects
against thrombosis, stroke, and myocardial infarction, but is accompanied by a high incidence
of adverse events.1–3 During the first weeks of therapy, the international normalized ratio
(INR) is often out of range and risk of bleeding is increased. To reduce the risk of hemorrhage,
experts advocate prescribing the anticipated therapeutic dose to patients who are beginning
warfarin,4–7 but do not provide a strategy for estimating that dose. The purpose of this study
was to develop such a strategy.
Warfarin metabolism varies with single-nucleotide polymorphisms (SNPs) in the cytochrome
P450 (CYP) 2C9 gene.1,8–10 Two common CYP2C9 SNPs are associated with impaired
metabolism of S-warfarin, the more active enantiomer of warfarin. The SNP in exon 3
(CGT→TGT; Arg144Cys) is denoted as CYP2C9*2 while the SNP in exon 7 (ATT→CTT;
Ile359Leu) is called CYP2C9*3. Patients with one or two of these SNPs have reduced warfarin
metabolism and a two- to threefold elevated risk of an adverse event when beginning warfarin.
1,10,11 Compared to CYP2C9 SNPs, SNPs in VKORC1 may be more important because the
latter gene codes for the enzyme inhibited by warfarin, vitamin K epoxide reductase
(VKORC1). Recently, we and others retrospectively identified novel VKORC1 SNPs that
correlated with warfarin sensitivity.12–16 Other factors thought to affect warfarin dose include
age, body size, smoking status, prior venous thromboembolism, race, and certain medications
such as amiodarone.7,8
In this report, we develop a warfarin-dosing algorithm by combining CYP2C9 and VKORC1
genotype status with relevant clinical factors8 and prospectively validate the dosing algorithm
in patients initiating warfarin therapy.
RESULTS
In the derivation cohort (N = 1,015), the daily therapeutic warfarin dose ranged from 1 to 18
mg/day. The mean age was 65 (range of 18−93); 83% were Caucasian, and 64% were male.
The (geometric) mean daily warfarin dose was 4.8 mg (Table 1). The most common indications
for warfarin therapy were atrial fibrillation (N = 392) and prior venous thromboembolism (N
= 376; 13 of whom also had atrial fibrillation). Patients in the validation cohort (N = 292) were
younger, more often female, and had more often (77%) undergone joint replacement as their
indication for warfarin therapy (Table 1).
VKORC1 alleles were highly heterogeneous (Table 2), reflecting their original selection as
common (>5% allele frequency), informative tagging SNPs (Table 2).12 VKORC1 3673G>A
was in high linkage disequilibrium with VKORC1 6853G>C (D’ = 0.97). In both cohorts, all
alleles were in Hardy–Weinberg equilibrium. Genotype data from all participants at
Washington University and University of Florida have been submitted to the PharmGKB
(accession numbers: PS207479 and PS207480 pending).
Pharmacogenetic model development
The VKORC1 3673G>A SNP was the first variable to enter the stepwise regression model
(Table 3); each VKORC1 3673A allele was associated with a 28% reduction (95% confidence
interval 25−30%) in the therapeutic warfarin dose. Once VKORC1 3673G>A entered the
model, none of the other VKORC1 SNPs was an independent predictor of warfarin dose. Body
surface area (BSA) was the second variable to enter the model, and each 0.25 m2 increase in
BSA was associated with an 11% (95% confidence interval 9−14%) increase in the therapeutic
warfarin dose. CYP2C9*3 was associated with a 33% (95% confidence interval 29−37%)
decrement, and CYP2C9*2 with a −19% (−22 to −15%) decrement in the warfarin dose per
allele. Other factors that entered the regression model were: target INR, amiodarone usage,
smoking status, race, and prior venous thromboembolism as the indication for warfarin therapy.
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Overall, the pharmacogenetic model contained 10 significant variables and explained more
than half of the variance in the therapeutic warfarin dose (R2 = 53.1%). Interaction terms
between the genotype and key medications were not statistically significant. Once VKORC1
3673G>A entered the model, VKORC1 haplotype12 was not an independent predictor of dose.
To quantify the benefit of incorporating genotype when estimating the therapeutic warfarin
dose, we excluded genetic factors and repeated the stepwise regression in the derivation cohort.
This clinical algorithm without genetic factors explained 21.5% of the variance (R2) in the
derivation cohort. The optimal clinical warfarin dose (mg/day) was:
where exp is the exponential function; BSA is in m2; race is 1 if African American (0
otherwise); target INR is the desired INR (e.g., 2.5); amiodarone is 1 if the patient is taking
that drug (and 0 otherwise); and DVT/PE is 1 if the indication for warfarin is deep venous
thrombosis (DVT) or pulmonary embolism (PE). The accuracy of the derived
pharmacogenetics model depended on race: R2 was 57% in 838 Caucasian participants and
31% in 153 African-American patients.
Validation cohort
In the validation cohort (Figure 1), the therapeutic dose correlated significantly (P < 0.001)
more with the pharmacogenetic predicted dose (R2 = 54%) than with the clinical predicted dose
(R2 = 17%; P < 0.001). The pharmacogenetic predicted dose also had a significantly lower
prediction error (Table 4). In the validation cohort, the R2 was 40% in 45 African-American
patients and 55% in 242 Caucasian participants.
For prospective patients who were dosed pharmacogenetically, we prescribed the
pharmacogenetic dose using the dosing equation from the derivation cohort (Table 3) or from
a preliminary version of this equation that was nearly identical (absolute mean difference =
0.1 mg/day). We did not decrease the very first warfarin dose to account for CYP2C9*2 or
CYP2C9*3 alleles for logistic and pharmacologic reasons. Logistically, in 62 (21%) patients,
CYP2C9 genotype was not available when the first dose was prescribed. Pharmacologically,
we wished to avoid a delay until reaching a therapeutic INR that can be caused by initially
prescribing the small predicted dose in slow metabolizers.17 Following this initial dose, we
prescribed the pharmacogenetically estimated dose (rounded to the nearest 0.5 mg) for 2
additional days with regular INR monitoring. If the INR was rising gradually, patients in the
prospective cohort continued on the pharmacogenetic dose, but otherwise clinicians adjusted
that dose on day 4. During the 30-day follow-up, two patients dosed prospectively had a major
hemorrhage or PE and three patients had a symptomatic DVT. None of the 43 individuals dosed
prospectively in the validation cohort who stopped warfarin prior to becoming therapeutic
suffered an adverse event.
DISCUSSION
For several reasons, warfarin is the ideal drug to test the hypothesis that pharmacogenetics can
reduce drug toxicity: it is commonly prescribed, has a narrow therapeutic/toxic ratio, and is
affected by common genetic polymorphisms. Using clinical factors alone we explained 17
−21% of the variability in the therapeutic warfarin dose, similar to other clinical algorithms.
18 However, by including CYP2C9 and VKORC1 genotypes, we could explain 53−54% of this
variability. These encouraging results are similar to conclusions of smaller, retrospective
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studies of homogenous populations that found that the addition of genetic information
substantially reduces the unknown intersubject variability in warfarin dose.13,19,20 These
previous studies did not provide prospectively validated algorithms for individualized warfarin
dosing, but made it clear that this issue had to be addressed.
In the present study, the most important factor in predicting the warfarin dose was VKORC1
3673G>A (located 1,639 bases upstream of the translation start site of VKORC1). This
polymorphism alters a VKORC1 transcription factor binding site15 and haplotypes associated
with the A allele result in lower VKORC1 mRNA expression in human liver.12 This change
in gene expression likely lowers the steady-state concentration of tissue vitamin K epoxide
reductase, the rate-limiting enzyme in the vitamin K cycle.21 The clinical effect was that
individuals with this allele were more susceptible to inhibition by warfarin, resulting in a 28%
decrease in the therapeutic warfarin dose per allele. Because of this decrease and the prevalence
of the VKORC1 3673G>A (Table 2), this SNP was the most important predictor of dose at the
time of warfarin initiation. We confirmed that this SNP is present at a low frequency in African-
American patients and intermediate frequency in Caucasian patients, consistent with previous
work.12,16,22 Genotyping of this single informative VKORC1 SNP should simplify clinical
genetic testing and implementation of pharmacogenetics-based therapy.
Each CYP2C9*2 and CYP2C9*3 allele predicted 19 and 33% reductions (respectively) in the
therapeutic dose of warfarin. These alleles correlate with slower clearance of the S-warfarin
enantiomer,19,23 a longer drug half-life, and a delay until stable dosing.1,22 To ameliorate
this delay, we gave a slightly greater first dose in poor warfarin metabolizers; we did not reduce
their initial dose despite the presence of CYP2C9*2 and/or CYP2C9*3.
In contrast to previous single-center studies of Caucasian patients,13,19,20 we genotyped a
diverse, multicenter cohort. To further enhance generalizability, we included patients from
multiple anticoagulation centers regardless of their comorbid conditions, target INR, and
concomitant therapy. To improve clinical usefulness, we focused on the effects of SNPs that
were suspected to be clinically relevant. One interesting result was the inclusion of the
VKORC1 3673 SNP as the only significant VKORC1 SNP in predicting warfarin dose. An
important strength of the current study is that we prospectively validated pharmacogenetics-
based warfarin therapy, thereby demonstrating its feasibility and safety.
All patients in the validation cohort received pharmacogenetic therapy without comparison to
patient management vianongenetic algorithms. In the future, other genetic variants may
strengthen the predictive power of pharmacogenetic warfarin therapy. For example, one study
showed significant associations between SNPs in factor VII and in γ−glutamyl carboxylase
and warfarin dose,24 but this association has not been replicated in a subset of our cohort (B.F.
Gage and C. Eby unpublished data) or in other cohorts.20 The factor II Thr165Met SNP,
previously associated with lower warfarin dose in studies of 147 Italian24 and 45 Japanese
patients,25 was of borderline significance in our univariate analysis and not an independent
predictor of warfarin dose. In keeping with our clinical focus, we did not consider additional
SNPs26,27 that are too rare to significantly improve dosing accuracy in the general population.
This study demonstrates the feasibility of pharmacogenetic warfarin therapy and supports the
need for a multicenter, randomized control trial quantifying its effect on laboratory and clinical
outcomes. Several companies have developed genotyping platforms to facilitate
pharmacogenetic dosing, and at least two have received Food and Drug Administration
approval. The Food and Drug Administration has also changed the Coumadin/warfarin labeling
to encourage lower initial doses in patients who have the VKORC1 3673G>A, CYP2C9*2, or
CYP2C9*3 allele.
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Two recent trials have randomized patients to pharmacogenetic vs. clinically-based warfarin
initiation but had conflicting findings. Caraco and colleagues at Hadassah University found
that CYP2C9 genotyping improved INR control and reduced minor (but not major) bleeding
compared to dosing by a computerized clinical algorithm.28 In the other randomized trial,
Anderson and colleagues in Utah found no significant benefit of pharmacogenetic vs. clinically
dosed warfarin.29 The studies were similarly sized—each having ∼100 patients per treatment
arm. The Anderson-dosing algorithm had an R2 of 47%; Caraco did not report the accuracy of
their algorithm, but a similar CYP2C9-dosing algorithm had an R2 of 39%.8 Given these
findings, a multicenter randomized and controlled trial is needed to quantify how
pharmacogenetic therapy affects INR control and clinical adverse events.
To facilitate a trial and the use of the dosing algorithms in this report, we have developed a
nonprofit website, http://www.WarfarinDosing.org. While the genotyping is pending,
WarfarinDosing.org estimates the warfarin dose using the clinical algorithm in this report.
Once genotype is available, WarfarinDosing.org uses the more accurate pharmacogenetic
algorithm (Table 3). If an INR is available after three doses, WarfarinDosing.org uses a
pharmacogenetic algorithm and the INR response to estimate the therapeutic dose (R2 = 79%).
30 A randomized controlled trial should test the hypothesis that pharmacogenetic dosing
improves laboratory and clinical outcomes in patients beginning warfarin for a variety of
indications. The National Institutes of Health has announced their intention to fund such a trial
via RFP-NHLBI-HV-08−03.
METHODS
From individuals in the derivation cohort (1,015 participants who had therapeutic warfarin
doses), we collected DNA and clinical factors to develop a warfarin-dosing algorithm. In the
validation cohort, we validated this algorithm prospectively, by prescribing pharmacogenetics-
based warfarin therapy in 292 patients. The research protocol was approved by the Human
Subjects’ Committee at the participating medical centers. All subjects gave written, informed
consent.
Derivation cohort
We genotyped adult patients who had their warfarin therapy managed at one of the
anticoagulation clinics affiliated with Barnes–Jewish Hospital at Washington University
Medical Center (St. Louis), the University of Florida (Gainesville), or the Anticoagulation
Clinics of North America (San Antonio), including some patients in prior studies.11,12,16 The
derivation cohort also included 203 additional participants from the PREVENT (PREvention
of VENous Thromboembolism) study who were randomized to long-term, low-intensity
warfarin therapy (target INR 1.5−2.0) for prevention of recurrent venous thromboembolism.
31 To control for the lower target INR in these patients (and higher target INR in participants
with mechanical heart valves), we included target INR in the regression equation. To prevent
referral bias, we excluded four participants who had been referred for extraordinary warfarin
doses (<1 or >20 mg/day). As in our prior work,30,32 therapeutic dose was defined as the
warfarin dose (unchanged for at least 6 days), which resulted in an INR that was between 70
and 130% of the target INR (i.e., in the range of 1.8−3.2 for someone with a target INR of 2.5).
Validation cohort
To validate the dosing algorithm, we recruited 335 patients who were scheduled to begin
warfarin therapy for a variety of medical and surgical indications at Barnes–Jewish Hospital,
295 of whom we dosed prospectively. We excluded patients who had contraindications to 1
month of warfarin therapy and patients whose therapeutic warfarin dose was known from prior
therapy. For our calculation of dosing accuracy, we excluded patients who stopped their
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warfarin therapy before achieving a therapeutic dose (N = 292). To improve generalizability,
we included patients regardless of comorbid conditions and concomitant medications. The
Barnes–Jewish Hospital Anticoagulation Service prospectively followed all patients in the
validation cohort for symptomatic adverse events; we did not screen for asymptomatic
thromboses.
Genotyping
We obtained 15-ml mouthwash samples from University of Florida participants (N = 327) and
10-ml whole blood in EDTA or sodium cit-rate tubes from other participants (N = 980). After
centrifugation, we isolated genomic DNA from buccal cells or buffy coat. We genotyped for
CYP2C9*2[rs1799853] using PCR/restriction fragment length polymorphism and
Pyrosequencing.8,12,33–35 We also Pyrosequenced all other SNPs in the validation cohort
(listed with dbSNP reference SNP identifiers): CYP2C9*3[rs1057910], CYP2C9*5
[rs1057910], VKORC1 C861A [rs17880887], VKORC1 G3673A [rs9923231; more recently
designated as –1639 G>A], VKORC1 A5808C [rs2884737], VKORC1 G6853C [rs8050894],
VKORC1 G9041A [rs7294], and one factor II variant (C/T Thr/Met; rs5896)24 that was
associated with warfarin sensitivity. We performed and interpreted genotyping while blinded
to clinical and demographic variables.
In the validation cohort, we genotyped for those SNPs that were significant predictors of the
warfarin dose in the derivation cohort using three different methods: (i) melting curve analysis
on a SmartCycler (Cepheid, Sunnyvale, CA),30 (ii) Invader assay (Third Wave Technologies,
Madison, WI) with the TECAN GENios FL fluorescence plate reader (Zurich, Switzerland),
or (iii) INFINITI analyzer (Autogenomics, Carlsbad, CA). In blinded comparisons, genotyping
was 99−100% accurate for all methods.36
Clinical variables
Using a paper-based survey, we collected demographic variables, laboratory data, smoking
status, and key interacting medications8 (including aspirin, amiodarone, simvastatin, or
fluvastatin) (Table 1). We used height and weight to calculate BSA,37 which correlated more
strongly with warfarin dose than either variable alone. We used continuous variables for
warfarin dose, age, and target INR (which was 1.75 for PREVENT participants and 2.5 for
most others).
Statistical analyses
In the derivation cohort, we used stepwise regression to derive the pharmacogenetic model that
predicted the therapeutic warfarin dose. To use an additive genetic model, we coded the number
of variant alleles at each locus as 0, 1, or 2. We tested for the effect of several clinical and
demographic variables: African-American race, Hispanic ethnicity, age, gender, BSA, PVT,
target INR, and use of aspirin, amiodarone, and simvastatin, or fluvastatin. The genetic factors
were CYP2C9*2, CYP2C9*3, CYP2C9*5, VKORC1 861C>A, 3673G>A, 5808T>G,
6853G>C, 9041G>A, and F2 Thr165Met. We retained variables in the regression model if
they were significant (two-tailed P < 0.05) independent predictors of warfarin dose in the
derivation cohort. To assess model fit, we examined residuals, including partial residuals. To
improve model fit and limit heteroscedascity we used a logarithmic transformation of warfarin
dose.
We tested the regression model in an independent validation cohort (N = 335), where we
calculated the prediction error from the formula: |pharmacogenetics predicted dose—
therapeutic dose|. We also captured incident hemorrhages or thromboses in the 30 days after
warfarin initiation in patients (N = 295) who were prospectively dosed. We used
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bootstrapping38 to quantify the standard deviations of the prediction error and the R2. We
performed statistical analyses in SAS (Version 9; SAS Institute, Cary, NC).
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Scatter plot showing the relationship between the pharmacogenetics-predicted dose (horizontal
axis) and therapeutic dose (vertical axis) in the validation cohort.
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Table 1
Demographic and clinical factors of participants
Variable Derivation cohort N = 1,015 Validation cohort N = 292
Demographic variables
Age, mean (SD), year 65 (14) 57 (14)
Gender
    Women, N (%) 362 (36%) 152 (52%)
    Men, N (%) 653 (64%) 140 (48%)a
Race
    Caucasian, N (%) 838 (83%) 242 (83%)
    African American, N (%) 153 (15%) 45 (15%)
    Other or mixed race, N (%) 24 (2%) 5 (2%)
Hispanic ethnicity, N (%) 24 (2%) 2 (1%)
Clinical variables
    Therapeutic warfarin dose, geometric mean (SD), mg per day 4.8 (1.6) 4.8 (1.7)
    Therapeutic INR, mean (SD), units 2.2 (0.5) 2.2 (0.4)
    Target INR, mean (SD), units 2.4 (0.4) 2.3 (0.2)
    Prior DVT or pulmonary embolism 376 (37%) 29 (10%)a
    Body surface area, mean (SD), m2 2.0 (0.26) 2.0 (0.3)
    Prescribed aspirin, N (%) 224 (22%) 78 (27%)
    Current smokers, N (%) 131 (13%) 50 (17%)
    Takes simvastatin or fluvastatin, N (%) 192 (19%) 33 (11%)a
    Takes amiodarone, N (%) 36 (4%) 14 (5%)
DVT, deep venous thrombosis; INR, international normalized ratio; SD, standard deviation.
a
Denotes P ≤ 0.01 when comparing values from the two cohorts.
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Table 3
Warfarin-dosing equation in derivation cohort (N = 1,015)
Entry into model Variable Effect on warfarin dose R2 after entry P value
1 VKOR 3673G>A −28% (−30 to −25%) 25% <0.0001
2 BSA, per 0.25 m2 11% (9−14%) 34% <0.0001
3 CYP2C9*3 −33% (−37 to −29%) 40% <0.0001
4 Age, per decade −7% (−9 to −6%) 45% <0.0001
5 CYP2C9*2 −19% (−22 to −15%) 50% <0.0001
6 Target INR, per 0.5 increase 11% (7−14%) 51% <0.0001
7 Amiodarone −22% (−30% to −14%) 52% <0.0001
8 Current smoker 10% (3−16%) 52.4% 0.002
9 African-American race −9% (−14 to −3%) 52.8% 0.002
10 Venous thromboembolism 7% (1−13%) 53.1% 0.013
BSA, body surface area in meters2; DVT, deep venous thrombosis; INR, international normalized ratio; PE, pulmonary embolism; SNP, single-nucleotide
polymorphism. The optimal pharmacogenetics algorithm that estimated the daily warfarin dose (mg/day) was:
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Table 4
Dosing accuracy in validation cohort
Accuracy metric Pharmacogenetics Clinical P value
R2 (SD) 54% (5%) 17% (4%) <0.0001
Median (mean) absolute prediction error,
mg/day
1.0 (1.3) 1.5 (1.8) <0.001
SD, standard deviation.
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